Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SWICK, H. M.
Right arrow Articles by McQUILLEN, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SWICK, H. M.
Right arrow Articles by McQUILLEN, M. P.
NEUROLOGY 1976;26:205
© 1976 American Academy of Neurology

The use of steroids in the treatment of idiopathic polyneuritis

HERBERT M. SWICK, M.D. and MICHAEL P. McQUILLEN, M.D.

From the Departments of Neurology, University of Kentucky Medical Center, Lexington, and Medical College of Wisconsin, Milwaukee.

The efficacy of steroids in the treatment of acute idiopathic polyneuritis (Guillain-Barré syndrome) continues to be uncertain. Since 1965, 38 patients with idiopathic polyneuritis have been seen at the University of Kentucky Medical Center, and 16 of them were entered in a prospective double-blind study designed to assess the effectiveness of steroid therapy. Seriously ill patients were excluded from the study and most of them received steroids. In both the double-blind group and the entire group of patients, the time from onset of illness to recovery was significantly less in patients treated with steroids, although steroids did not alter the initial severity of illness or the duration of hospitalization.

Dr. Swick's address is Medical College of Wisconsin, Milwaukee Children's Hospital, 1700 West Wisconsin Ave., Milwaukee, Wl 53233.

This investigation was supported in part by Special Traineeship Award 1-F11-NSO 2463, NINDS, NIH.

This work was presented in part at the twenty-seventh annual meeting of the American Academy of Neurology, Bal Harbour, Florida, May 1975.

Received for publication May 27, 1975.




This article has been cited by other articles:


Home page
 BrainHome page
R. A. C. Hughes, A. V. Swan, J.-C. Raphael, D. Annane, R. van Koningsveld, and P. A. van Doorn
Immunotherapy for Guillain-Barre syndrome: a systematic review
Brain, September 1, 2007; 130(9): 2245 - 2257.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R.A.C. Hughes, E.F.M. Wijdicks, R. Barohn, E. Benson, D.R. Cornblath, A. F. Hahn, J.M. Meythaler, R.G. Miller, J.T. Sladky, and J.C. Stevens
Practice parameter: Immunotherapy for Guillain-Barre syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurology, September 23, 2003; 61(6): 736 - 740.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
J.B. Winer
Treatment of Guillain-Barre syndrome
QJM, November 1, 2002; 95(11): 717 - 721.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
P. O. Osterman, J. Fagius, J. Safwenberg, A. Danersund, B. G. Wallin, and L.-O. Nordesjo
Treatment of the Guillain-Barre Syndrome by Plasmapheresis
Arch Neurol, March 1, 1982; 39(3): 148 - 154.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1976 by AAN Enterprises, Inc.